<p><em>– 武田制药重新获得 XOMA Royalty 在 mezagitamab (TAK-079) 的大部分特许权收益 –</em></p>
<p><em>– XOMA Royalty 将有权根据与武田外部资产组合中九个开发阶段资产相关的里程碑和特许权收益分享获得付款 –</em></p>
<p>加利福尼亚州埃默里维尔，2025 年 12 月 30 日（全球新闻通讯）-- XOMA Royalty Corporation（纳斯达克：XOMA），这家生物技术特许权收益聚合公司，今天宣布通过一项战略特许权分享交易修订了其与武田于 2006 年建立的合作关系。武田对 XOMA Royalty 与 mezagitamab 相关的特许权和里程碑付款义务将减少，XOMA Royalty 将根据一篮子九个开发阶段资产获得低至中单数字的特许权收益和里程碑付款，这些资产属于武田的外部资产组合。</p>
<p>“我们继续寻找通过创造性交易来扩展和多样化我们的特许权和里程碑组合的方法，这对双方都有利，” XOMA Royalty 首席投资官 Brad Sitko 表示。“武田和 XOMA Royalty 有着长期的合作历史。通过修订我们的合作关系，我们能够将部分 mezagitamab 的经济利益返还给武田，同时也扩展和多样化 XOMA Royalty 在几个有趣的早期和晚期项目中的投资组合。”</p>
<p><strong>Mezagitamab</strong></p>
<p>在修订合作关系之前，XOMA Royalty 持有与 mezagitamab 相关的中单数字特许权和 1625 万美元的潜在里程碑。未来，XOMA Royalty 将保留对 mezagitamab 的低单数字特许权收益权和最高 1300 万美元的里程碑。</p>
<p><strong>武田外部资产组合中的开发阶段资产</strong></p>
<p><strong>Osavampator</strong></p>
<ul>
<li><strong>Neurocrine Biosciences</strong> 正在开发 osavampator，这是一种潜在的首创研究性 α-氨基-3-羟基-5-甲基-4-异噁唑丙酸 (AMPA) 正向别构调节剂 (PAM)，用于对主要抑郁症 (MDD) 治疗反应不足的患者。</li>
</ul>
<p><strong>Volixibat</strong></p>
<ul>
<li><strong>Mirum Pharmaceuticals</strong> 正在开发 volixibat，这是一种最小吸收的口服给药研究性疗法，旨在选择性抑制肠道胆盐转运蛋白 (IBAT)，用于原发性硬化性胆管炎 (PSC) 和原发性胆汁性胆管炎 (PBC)。</li>
</ul>
<p><strong>OHB-607 和五个早期阶段的 Oak Hill Bio 资产</strong></p>
<ul>
<li><strong>Oak Hill Bio</strong> 及其合作伙伴正在开发 OHB-607，这是一种重组人 IGF-1/IGFBP-3，用于预防早产儿的支气管肺发育不良。其他 Oak Hill Bio 资产有潜力产生特许权收益，涉及其他高未满足需求或罕见疾病领域。</li>
</ul>
<p><strong>REC-4881</strong></p>
<ul>
<li><strong>Recursion Pharmaceuticals</strong> 正在开发 REC-4881，这是一种研究性 MEK1/2 抑制剂，用于家族性腺瘤性息肉病，这是一种影响美国、法国、德国、意大利、西班牙和英国约 50,000 人的罕见肿瘤易感综合症。</li>
</ul>
<p><strong>关于 XOMA Royalty Corporation</strong></p>
<p>XOMA Royalty 是一家生物技术特许权收益聚合公司，在帮助生物技术公司实现改善人类健康目标方面发挥着独特的作用。XOMA Royalty 收购与已授权给制药或生物技术公司的预商业和商业治疗候选药物相关的潜在未来经济利益。当 XOMA Royalty 收购未来经济利益时，卖方将获得非稀释、无追索权的资金，可以用于推进其内部药物候选者或用于一般企业目的。XOMA Royalty 拥有广泛且不断增长的资产组合（资产定义为获得与基础治疗候选者的推进相关的潜在未来经济利益的权利）。有关 XOMA Royalty 及其投资组合的更多信息，请访问 www.xoma.com 或在 LinkedIn 上关注 XOMA Royalty Corporation。</p>
<p><strong>XOMA Royalty 前瞻性声明/说明性备注</strong></p>
<p>本新闻稿中包含的某些声明是根据 1933 年证券法第 27A 条和 1934 年证券交易法第 21E 条的定义的前瞻性声明，包括关于潜在商业和里程碑付款的时间和金额，以及与 mezagitamab、osavampator、volixibat、OHB-607 和 Oak Hill Bio 资产以及 REC-4881 相关的其他发展。在某些情况下，您可以通过诸如 “预期”、“打算”、“相信”、“估计”、“计划”、“寻求”、“预测”、“期望”、“可能”、“将”、“会”、“可以” 或 “应该” 等术语或这些术语的否定形式或类似表达来识别这些前瞻性声明。这些前瞻性声明并不能保证 XOMA Royalty 的表现，您不应对这些声明过于依赖。这些声明基于可能不准确的假设，实际结果可能因生物技术行业固有的某些风险而与预期有重大差异，包括与我们的产品候选者仍在开发中相关的事实，以及我们的许可方可能需要大量资金以继续开发，而这些资金可能不可用；我们不知道我们拥有所有权或特许权的产品是否会有或将继续有可行的市场；如果我们拥有特许权的治疗产品候选者未获得监管批准，我们的第三方许可方将无法将其推向市场。XOMA Royalty 满足这些期望的其他潜在风险在 XOMA Royalty 最近提交的 10-Q 表格和其他向证券交易委员会提交的文件中有更详细的描述。在考虑 XOMA Royalty 的前景时，请仔细考虑这些风险。本新闻稿中的任何前瞻性声明仅代表 XOMA Royalty 在本新闻稿日期的信念和假设，不应被视为其在任何后续日期的观点。XOMA Royalty 不承担更新任何前瞻性声明的义务，除非法律要求。</p>
<p>说明性备注：本新闻稿中提到的 “投资组合” 仅指与一系列正在开发的药品相关的里程碑和/或特许权权益。 本新闻稿中提到的 “资产” 仅指与单个正在开发的药品相关的里程碑和/或特许权权益。</p>
<p>截至本新闻稿日期，XOMA Royalty 的里程碑和特许权投资组合中的商业资产包括 VABYSMO®（faricimab-svoa）、OJEMDA™（tovorafenib）、MIPLYFFA™（arimoclomol）、XACIATO™（克林霉素磷酸盐）阴道凝胶 2%、IXINITY® [凝血因子 IX（重组）] 和 DSUVIA®（舌下用舒芬太尼片）。投资组合中的所有其他资产均为研究性化合物。尚未确定其疗效和安全性。没有保证任何研究性化合物会商业化。</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>XOMA Royalty 投资者联系：</strong></td>
<td><strong>XOMA Royalty 媒体联系：</strong></td>
</tr>
<tr>
<td>Juliane Snowden</td>
<td>Kathy Vincent</td>
</tr>
<tr>
<td>XOMA Royalty Corporation</td>
<td>KV Consulting &amp; Management</td>
</tr>
<tr>
<td>+1-646-438-9754</td>
<td>kathy@kathyvincent.com</td>
</tr>
<tr>
<td>juliane.snowden@xoma.com</td>
<td></td>
</tr>
</tbody>
</table>
<hr/>
<p>1 https://ir.recursion.com/news-releases/news-release-details/preliminary-phase-1b2-data-rec-4881-familial-adenomatous</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE9EQTJPQ00zTXpNNU1qUTVJekl3TWpjd01UWT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE9EQTJPQ00zTXpNNU1qUTVJekl3TWpjd01UWT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZmUzM2ZlNzEtOTgzYy00YjFmLWI5MmItODMyZTkyZTdjMmRlLTEwMzg3NTMtMjAyNS0xMi0zMC1lbg==/tiny/XOMA-Royalty-Corporation.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZmUzM2ZlNzEtOTgzYy00YjFmLWI5MmItODMyZTkyZTdjMmRlLTEwMzg3NTMtMjAyNS0xMi0zMC1lbg==/tiny/XOMA-Royalty-Corporation.png"/></p>

标记临床研究

<p>XOMA Royalty Corporation 已修订与武田制药的合作协议，重新获得 mezagitamab 的多数特许权利益。XOMA 现在将从武田的九个开发阶段资产中获得低至中个位数的特许权使用费和里程碑付款。这些变更减少了武田的付款义务，同时使 XOMA 的特许权使用费组合更加多样化。XOMA 将保留 mezagitamab 的低个位数特许权使用费和高达 1300 万美元的里程碑付款。这一战略交易旨在使双方受益，并增强 XOMA 的资产组合</p>

<p><em>– Takeda regains a majority of XOMA Royalty’s royalty interest in mezagitamab (TAK-079) –</em></p>
<div class="lb-trans"><p><em>– 武田制药重新获得 XOMA Royalty 在 mezagitamab (TAK-079) 的大部分特许权收益 –</em></p>
</div><p><em>– XOMA Royalty will be entitled to payments based on a share of milestones and royalties associated with nine development-stage assets held within Takeda’s externalized assets portfolio –</em></p>
<div class="lb-trans"><p><em>– XOMA Royalty 将有权根据与武田外部资产组合中九个开发阶段资产相关的里程碑和特许权收益分享获得付款 –</em></p>
</div><p>EMERYVILLE, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has amended its collaboration, originally established in 2006, with Takeda through a strategic royalty share transaction. Takeda’s royalty and milestone payment obligations to XOMA Royalty related to mezagitamab will be reduced, and XOMA Royalty will receive payments based on low to mid-single-digit royalties and milestones across a basket of nine development-stage assets that are held within Takeda’s externalized assets portfolio.</p>
<div class="lb-trans"><p>加利福尼亚州埃默里维尔，2025 年 12 月 30 日（全球新闻通讯）-- XOMA Royalty Corporation（纳斯达克：XOMA），这家生物技术特许权收益聚合公司，今天宣布通过一项战略特许权分享交易修订了其与武田于 2006 年建立的合作关系。武田对 XOMA Royalty 与 mezagitamab 相关的特许权和里程碑付款义务将减少，XOMA Royalty 将根据一篮子九个开发阶段资产获得低至中单数字的特许权收益和里程碑付款，这些资产属于武田的外部资产组合。</p>
</div><p>“We continue to find ways to expand and diversify our royalty and milestone portfolio through creative transactions that are beneficial to both parties,” stated Brad Sitko, Chief Investment Officer of XOMA Royalty. “Takeda and XOMA Royalty have a long history of collaboration. By amending our collaboration, we are able to return a portion of our mezagitamab economics to Takeda, while also expanding and diversifying XOMA Royalty’s portfolio across several interesting early- and late-stage programs.”</p>
<div class="lb-trans"><p>“我们继续寻找通过创造性交易来扩展和多样化我们的特许权和里程碑组合的方法，这对双方都有利，” XOMA Royalty 首席投资官 Brad Sitko 表示。“武田和 XOMA Royalty 有着长期的合作历史。通过修订我们的合作关系，我们能够将部分 mezagitamab 的经济利益返还给武田，同时也扩展和多样化 XOMA Royalty 在几个有趣的早期和晚期项目中的投资组合。”</p>
</div><p><strong>Mezagitamab</strong></p>
<div class="lb-trans"><p><strong>Mezagitamab</strong></p>
</div><p>Prior to amending the collaboration, XOMA Royalty held a mid-single digit royalty and $16.25 million in potential milestones associated with mezagitamab. Going forward, XOMA Royalty will retain a low single-digit royalty entitlement on mezagitamab and up to $13.0 million in milestones.</p>
<div class="lb-trans"><p>在修订合作关系之前，XOMA Royalty 持有与 mezagitamab 相关的中单数字特许权和 1625 万美元的潜在里程碑。未来，XOMA Royalty 将保留对 mezagitamab 的低单数字特许权收益权和最高 1300 万美元的里程碑。</p>
</div><p><strong>Development-Stage Assets from Takeda’s Externalized Assets Portfolio</strong></p>
<div class="lb-trans"><p><strong>武田外部资产组合中的开发阶段资产</strong></p>
</div><p><strong>Osavampator</strong></p>
<div class="lb-trans"><p><strong>Osavampator</strong></p>
</div><ul>
<li><strong>Neurocrine Biosciences</strong> is developing osavampator, a potential first-in-class, investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) positive allosteric modulator (PAM) for patients who have inadequate response to treatment for major depressive disorder (MDD).</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>Neurocrine Biosciences</strong> 正在开发 osavampator，这是一种潜在的首创研究性 α-氨基-3-羟基-5-甲基-4-异噁唑丙酸 (AMPA) 正向别构调节剂 (PAM)，用于对主要抑郁症 (MDD) 治疗反应不足的患者。</li>
</ul>
</div><p><strong>Volixibat</strong></p>
<div class="lb-trans"><p><strong>Volixibat</strong></p>
</div><ul>
<li><strong>Mirum Pharmaceuticals</strong> is developing volixibat, a minimally absorbed, orally administered investigational therapy designed to selectively inhibit ileal bile acid transporter (IBAT), for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC).</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>Mirum Pharmaceuticals</strong> 正在开发 volixibat，这是一种最小吸收的口服给药研究性疗法，旨在选择性抑制肠道胆盐转运蛋白 (IBAT)，用于原发性硬化性胆管炎 (PSC) 和原发性胆汁性胆管炎 (PBC)。</li>
</ul>
</div><p><strong>OHB-607 and five early-stage Oak Hill Bio assets</strong></p>
<div class="lb-trans"><p><strong>OHB-607 和五个早期阶段的 Oak Hill Bio 资产</strong></p>
</div><ul>
<li><strong>Oak Hill Bio</strong> and their partner are developing OHB-607, a recombinant human IGF-1/IGFBP-3 for the prevention of bronchopulmonary dysplasia in premature infants. Additional Oak Hill Bio assets that have the potential to generate royalties address other high unmet need or rare disease areas.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>Oak Hill Bio</strong> 及其合作伙伴正在开发 OHB-607，这是一种重组人 IGF-1/IGFBP-3，用于预防早产儿的支气管肺发育不良。其他 Oak Hill Bio 资产有潜力产生特许权收益，涉及其他高未满足需求或罕见疾病领域。</li>
</ul>
</div><p><strong>REC-4881</strong></p>
<div class="lb-trans"><p><strong>REC-4881</strong></p>
</div><ul>
<li><strong>Recursion Pharmaceuticals</strong> is developing REC-4881, an investigational MEK1/2 inhibitor for familial adenomatous polyposis, a rare tumor predisposition syndrome affecting approximately 50,000 people in the U.S., France, Germany, Italy, Spain, and the UK1.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>Recursion Pharmaceuticals</strong> 正在开发 REC-4881，这是一种研究性 MEK1/2 抑制剂，用于家族性腺瘤性息肉病，这是一种影响美国、法国、德国、意大利、西班牙和英国约 50,000 人的罕见肿瘤易感综合症。</li>
</ul>
</div><p><strong>About XOMA Royalty Corporation</strong></p>
<div class="lb-trans"><p><strong>关于 XOMA Royalty Corporation</strong></p>
</div><p>XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the sellers receive non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. XOMA Royalty has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about XOMA Royalty and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.</p>
<div class="lb-trans"><p>XOMA Royalty 是一家生物技术特许权收益聚合公司，在帮助生物技术公司实现改善人类健康目标方面发挥着独特的作用。XOMA Royalty 收购与已授权给制药或生物技术公司的预商业和商业治疗候选药物相关的潜在未来经济利益。当 XOMA Royalty 收购未来经济利益时，卖方将获得非稀释、无追索权的资金，可以用于推进其内部药物候选者或用于一般企业目的。XOMA Royalty 拥有广泛且不断增长的资产组合（资产定义为获得与基础治疗候选者的推进相关的潜在未来经济利益的权利）。有关 XOMA Royalty 及其投资组合的更多信息，请访问 www.xoma.com 或在 LinkedIn 上关注 XOMA Royalty Corporation。</p>
</div><p><strong>XOMA Royalty Forward-Looking Statements/Explanatory Notes</strong></p>
<div class="lb-trans"><p><strong>XOMA Royalty 前瞻性声明/说明性备注</strong></p>
</div><p>Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the timing and amount of potential commercial and milestone payments to XOMA Royalty and other developments related to mezagitamab, osavampator, volixibat, OHB-607 and the Oak Hill Bio assets, and REC-4881. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will”, “would,” “could” or “should,” the negative of these terms or similar expressions. These forward-looking statements are not a guarantee of XOMA Royalty’s performance, and you should not place undue reliance on such statements. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that our product candidates subject to out-license agreements are still being developed, and our licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; and if the therapeutic product candidates to which we have a royalty interest do not receive regulatory approval, our third-party licensees will not be able to market them. Other potential risks to XOMA Royalty meeting these expectations are described in more detail in XOMA Royalty's most recent filing on Form 10-Q and in other filings with the Securities and Exchange Commission. Consider such risks carefully when considering XOMA Royalty's prospects. Any forward-looking statement in this press release represents XOMA Royalty's beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA Royalty disclaims any obligation to update any forward-looking statement, except as required by applicable law.</p>
<div class="lb-trans"><p>本新闻稿中包含的某些声明是根据 1933 年证券法第 27A 条和 1934 年证券交易法第 21E 条的定义的前瞻性声明，包括关于潜在商业和里程碑付款的时间和金额，以及与 mezagitamab、osavampator、volixibat、OHB-607 和 Oak Hill Bio 资产以及 REC-4881 相关的其他发展。在某些情况下，您可以通过诸如 “预期”、“打算”、“相信”、“估计”、“计划”、“寻求”、“预测”、“期望”、“可能”、“将”、“会”、“可以” 或 “应该” 等术语或这些术语的否定形式或类似表达来识别这些前瞻性声明。这些前瞻性声明并不能保证 XOMA Royalty 的表现，您不应对这些声明过于依赖。这些声明基于可能不准确的假设，实际结果可能因生物技术行业固有的某些风险而与预期有重大差异，包括与我们的产品候选者仍在开发中相关的事实，以及我们的许可方可能需要大量资金以继续开发，而这些资金可能不可用；我们不知道我们拥有所有权或特许权的产品是否会有或将继续有可行的市场；如果我们拥有特许权的治疗产品候选者未获得监管批准，我们的第三方许可方将无法将其推向市场。XOMA Royalty 满足这些期望的其他潜在风险在 XOMA Royalty 最近提交的 10-Q 表格和其他向证券交易委员会提交的文件中有更详细的描述。在考虑 XOMA Royalty 的前景时，请仔细考虑这些风险。本新闻稿中的任何前瞻性声明仅代表 XOMA Royalty 在本新闻稿日期的信念和假设，不应被视为其在任何后续日期的观点。XOMA Royalty 不承担更新任何前瞻性声明的义务，除非法律要求。</p>
</div><p>EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.</p>
<div class="lb-trans"><p>说明性备注：本新闻稿中提到的 “投资组合” 仅指与一系列正在开发的药品相关的里程碑和/或特许权权益。 本新闻稿中提到的 “资产” 仅指与单个正在开发的药品相关的里程碑和/或特许权权益。</p>
</div><p>As of the date of this press release, the commercial assets in XOMA Royalty’s milestone and royalty portfolio are VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), MIPLYFFA™ (arimoclomol), XACIATO™ (clindamycin phosphate) vaginal gel 2%, IXINITY® [coagulation factor IX (recombinant)], and DSUVIA® (sufentanil sublingual tablet). All other assets in the milestone and royalty portfolio are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of the investigational compounds will become commercially available.</p>
<div class="lb-trans"><p>截至本新闻稿日期，XOMA Royalty 的里程碑和特许权投资组合中的商业资产包括 VABYSMO®（faricimab-svoa）、OJEMDA™（tovorafenib）、MIPLYFFA™（arimoclomol）、XACIATO™（克林霉素磷酸盐）阴道凝胶 2%、IXINITY® [凝血因子 IX（重组）] 和 DSUVIA®（舌下用舒芬太尼片）。投资组合中的所有其他资产均为研究性化合物。尚未确定其疗效和安全性。没有保证任何研究性化合物会商业化。</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>XOMA Royalty Investor Contact:</strong></td>
<td><strong>XOMA Royalty Media Contact:</strong></td>
</tr>
<tr>
<td>Juliane Snowden</td>
<td>Kathy Vincent</td>
</tr>
<tr>
<td>XOMA Royalty Corporation</td>
<td>KV Consulting &amp; Management</td>
</tr>
<tr>
<td>+1-646-438-9754</td>
<td>kathy@kathyvincent.com</td>
</tr>
<tr>
<td>juliane.snowden@xoma.com</td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>XOMA Royalty 投资者联系：</strong></td>
<td><strong>XOMA Royalty 媒体联系：</strong></td>
</tr>
<tr>
<td>Juliane Snowden</td>
<td>Kathy Vincent</td>
</tr>
<tr>
<td>XOMA Royalty Corporation</td>
<td>KV Consulting &amp; Management</td>
</tr>
<tr>
<td>+1-646-438-9754</td>
<td>kathy@kathyvincent.com</td>
</tr>
<tr>
<td>juliane.snowden@xoma.com</td>
<td></td>
</tr>
</tbody>
</table>
</div><hr/>
<div class="lb-trans"><hr/>
</div><p>1 https://ir.recursion.com/news-releases/news-release-details/preliminary-phase-1b2-data-rec-4881-familial-adenomatous</p>
<div class="lb-trans"><p>1 https://ir.recursion.com/news-releases/news-release-details/preliminary-phase-1b2-data-rec-4881-familial-adenomatous</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE9EQTJPQ00zTXpNNU1qUTVJekl3TWpjd01UWT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxODA2OCM3MzM5MjQ5IzIwMjcwMTY="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZmUzM2ZlNzEtOTgzYy00YjFmLWI5MmItODMyZTkyZTdjMmRlLTEwMzg3NTMtMjAyNS0xMi0zMC1lbg==/tiny/XOMA-Royalty-Corporation.png" alt="" original-src="https://ml.globenewswire.com/media/ZmUzM2ZlNzEtOTgzYy00YjFmLWI5MmItODMyZTkyZTdjMmRlLTEwMzg3NTMtMjAyNS0xMi0zMC1lbg==/tiny/XOMA-Royalty-Corporation.png"/></p>

标记临床研究和武田执行战略特许权使用费共享交易，并修改现有的 Mezagitamab 协议 | XOMA 股票新闻